Navigation Links
Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List
Date:12/2/2009

NANJING, China, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that 105 of its drugs have been included in China's National Drug Reimbursement List ("NDRL"), which was issued by China's Ministry of Human Resources and Social Security on November 30, 2009.

Of the 105 drugs that have been included on the NDRL, the actively marketed drugs are Edaravone (Bicun and Yidasheng), Nedaplatin (Jiebaishu), Diclofenac (Yingtaiqing), Amoxicillin (Zailin), Biapenem (Anxin), Amoxicillin and Clavulanate (Anqi), Levamlodipine (Xinta), Alfacalcidol (Faneng), Smectite (Biqi), and Kechuanning. Simcere's newly acquired Rosuvastatin is one of the 105 drugs.

The updated NDRL consists of 2,151 drugs and is an important component of the healthcare reform plan in China. The Chinese government is aiming for healthcare coverage to reach at least 90 per cent of the population by the end of 2010.

Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group, commented, "We are delighted to have 105 drugs included in China's National Drug Reimbursement List. Simcere will continue to maximise opportunities to translate this good news into increased product sales. We are confident that the inclusion of so many of our drugs on the NDRL will have a positive impact and that Simcere will benefit from China's ongoing healthcare reform over the mid-to-long term."

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Excha
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
2. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
3. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
4. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
5. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
6. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
7. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
8. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
9. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
10. Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008
11. Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: ... develops and commercializes proprietary technologies and products for ... has received approval from the TSX Venture Exchange ... share purchase warrants ("the Warrants") of the Company, ... May 2013 private placement financing. Each ...
(Date:4/17/2015)... BellBrook Labs announced today that ... the powerful Orthogonal Pooled Screening (OPS) Platform developed ... the Lankenau Institute for Medical Research (LCGC) in ... improve successful drug discovery outcomes using far more ... libraries available nowhere else, coupled to a state-of-the-art ...
(Date:4/16/2015)... April 16, 2015 Capillus, LLC ... and physician network in Europe and Asia. The ... appointed Fernando Bermúdez, former Business Development Director of ... industry veteran, Mr. Bermúdez’s professional achievements include increasing ... Spain, while also penetrating the Portuguese marketplace with ...
(Date:4/16/2015)... OncoTAb, Inc., a University ... company, announced today the appointment of physician and ... Operating Officer (COO). Cooper brings to OncoTAb more ... diagnostic and biotechnology platforms in the fields of ... career transcends the field of medical and scientific ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2
... Antidepressant Can Help Adults Living With ... Relief -(1), PRINCETON, N.J. and TOKYO, Nov. ... and Otsuka Pharmaceutical Co.,Ltd. announced today that the ... New Drug Application for ABILIFY(R),(aripiprazole) as adjunctive, or ...
... BB: CLBE), an emerging life sciences company ( http://www.CalbaTech.com ... stem cells for,possible future therapeutic uses and providing products ... to academic,institutions, said today in its 10Q filing with ... be profitable in 2007. The addition of sales ...
... will present at the Piper Jaffray 19th Annual Healthcare ... Pierre Hotel in New York. John L.,Bishop, Chief Executive ... Chief Financial Officer, will provide a corporate overview. ... be,accessed on Cepheid,s Web site at http://www.cepheid.com ...
Cached Biology Technology:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 2U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 3U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 4U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 5U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 6U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 7U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 8U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 9CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 2CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 3Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference 2
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)... 2015 SoundView Technology Group issues a new research ... ) Wocket smart wallet. SoundView was one of the selected user ... with the Wocket in multiple scenarios and outlets. ... other retailers, making both debit and credit card payments.  ... "If the company meets their plans in 2015, it would ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... Wistar Institute have deciphered the structure of the active ... role in the development of nearly all human cancers. ... of new, broadly effective cancer drugs, as well as ... a decade to find drugs that shut down telomerasewidely ...
... have long known to be related to each other women ... Now, a master switch has been found in the brain of ... Biological Studies say it may work the same way in humans. ... Aug. 31 online edition of Nature Medicine , suggest that ...
... was reached by the Alliance for a Healthier Generation ... on "competitive foods" such as soft drinks at schools. ... the availability of soft drinks at school may not ... children. In a study of more than 4,000 ...
Cached Biology News:Landmark study opens door to new cancer, aging treatments 2Landmark study opens door to new cancer, aging treatments 3New master switch found in the brain that regulates appetite and reproduction 2New master switch found in the brain that regulates appetite and reproduction 3New master switch found in the brain that regulates appetite and reproduction 4
... Topo I, Wild Type ... Tris-HCl, 1 mM DTT, 200 µM EDTA, 20% ... topoisomerase I (Topo I) is a monomeric protein ... gene. It catalyzes the relaxation of both positive ...
RNase-Free DNase 50 l...
Request Info...
... is a DNA-dependent RNA polymerase which is ... It efficiently synthesizes in vitro transcripts from ... from a T7 promoter. Transcripts can ... in vitro translation, substrates in RNA processing ...
Biology Products: